Tempus AI Inc. (TEM) shares plunged 12.24% in after-hours trading on Monday following the company's report of wider-than-expected losses for the full year 2024, despite solid revenue growth.
The precision medicine technology company reported fourth-quarter revenue of $200.68 million, up 35.8% year-over-year, but missed analyst estimates of $203.12 million. For the full year 2024, revenue increased 30.4% to $693.4 million.
However, Tempus AI reported a net loss of $705.8 million for the full year 2024, including $547.7 million in stock-based compensation expenses. The adjusted EBITDA loss for 2024 was $104.7 million, an improvement of $49.5 million from the previous year but wider than expected.
In the fourth quarter, Tempus AI's net loss narrowed to $13.0 million from $50.5 million a year earlier, and the adjusted EBITDA loss improved to $7.8 million from $35.1 million in Q4 2023.
On a positive note, Tempus AI closed the acquisition of Ambry Genetics on February 3, 2025, and raised its revenue guidance for the full year 2025 to $1.24 billion, representing approximately 79% annual growth. The company also expects to achieve positive adjusted EBITDA of approximately $5 million in 2025, an improvement of around $110 million over 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.